Eli Lilly and Company said the EMA’s CHMP issued a positive opinion recommending expanded EU approval of Olumiant (baricitinib), an oral once-daily JAK inhibitor, for adolescents aged 12 to under 18 with severe alopecia areata. The recommendation is supported by 36-week Phase 3 BRAVE-AA-PEDS data showing 42.4 percent of patients on 4 mg and 27.4 percent on 2 mg achieved at least 80 percent scalp hair coverage versus 4.5 percent on placebo, with additional eyebrow and eyelash regrowth outcomes reported. Lilly also noted that 52-week efficacy and safety data were already presented in October 2025 at the Fall Clinical Dermatology Conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief on February 27, 2026, and is solely responsible for the information contained therein.
